Cinnarizine

General characteristics. Structure:

Active agent: Cinnarizine of 25,00 mg
Excipients: lactoses monohydrate (sugar milk) – 79,70 mg, cellulose microcrystallic – 25,00 mg, starch corn – 15,00 mg, povidone (polyvinylpirrolidone) – 3,00 mg, silicon dioxide colloid – 0,80 mg, magnesium stearate – 1,50 mg.
Description: tablets of color, white or white with a creamy shade, плоскоцилин drichesky with risky and a facet

Pharmacological properties:

The selection blocker of slow calcium channels, reduces receipt in cells of calcium ions and reduces their keeping in depot of a plasmolemma, reduces a tone of smooth muscles of arterioles, strengthens vazodilatiruyushchy effect of carbon dioxide. Directly influencing smooth muscles of vessels, reduces their reaction to biogenic substances (adrenaline, noradrenaline, dopamine, angiotensin, vasopressin). Has vasodilating effect (especially concerning brain vessels), without having significant effect on arterial pressure. Shows moderate anti-histamine activity, reduces excitability of a vestibular mechanism, lowers a tone of a sympathetic nervous system. It is effective both at initial, and at chronic insufficiency of cerebral circulation (including at patients in a residual stage of an ischemic stroke). At patients with disturbance of peripheric circulation improves blood supply of bodies and fabrics (including a myocardium). Increases elasticity of membranes of erythrocytes, their deformability, reduces viscosity of blood. Took away -
chivat resistance of muscles to a hypoxia.
Pharmacokinetics. Drug rezobirutsya in a stomach and intestines. The maximum concentration in a blood plasma after intake in 1-3 hours. Communication of Cinnarizine with proteins of plasma makes 91%. It is completely metabolized in a liver (by means of dealkylation). The elimination half-life is equal to 4 hours. It is removed in the form of metabolites: 1/3 - kidneys and 2/3 - with a fecal masses.

Indications to use:

Ischemic stroke, postinsultny states (including after a hemorrhagic stroke), a state after cherepnomozgovy injuries, distsirkulyatorny encephalopathy, vestibular disturbances (including Menyer's disease; dizziness, a sonitus, a nystagmus, nausea and vomiting of a labyrinth origin), prevention of kinetoz ("a road disease" - sea and aeroembolism), migraine (prevention of attacks), senile dementia: disturbances of peripheric circulation (the "alternating" lameness, the obliterating atherosclerosis obliterating a thromboangitis (Thrombangiitis obliterans), a Raynaud's disease, a diabetic angiopatiya, thrombophlebitis, trophic disturbances (including trophic and varicose ulcers, pregangrenous states).

Route of administration and doses:

Inside, it is desirable after food. At disturbance of blood circulation of a brain - on 25-50 mg (1-2 tablets) three times a day; at disturbance of peripheric circulation - on 50-75 mg (2-3 tablets) three times a day; at vestibular disturbances

- on 25 mg three times a day; at a kinetoza (a "road" disease): the adult - on 25 mg for half an hour before the road (if necessary repeated reception of 25 mg in 6 hours). A dose for children - ½ doses, recommended to adults. At high sensitivity to drug treatment is begun about ½ doses, increasing it gradually. A course of treatment from several weeks to several months.

Features of use:

In an initiation of treatment it is necessary to abstain from potentially dangerous types of activity demanding the increased concentration of attention and psychomotor reactions and also from alcohol intake. Due to the existence of antihistaminic effect, cinnarizine can affect result at anti-doping control of athletes (a false positive take), and also cinnarizine can level positive reactions when conducting skin diagnostic tests (in 4 days prior to a research treatment should be cancelled). At prolonged use carrying out control inspection of function of a liver, kidneys, pictures of peripheral blood is recommended. The patients having Parkinson's disease should appoint only when advantages of its appointment exceed possible risk of an aggravation of symptoms.

Side effects:

From a nervous system: drowsiness, fatigue, headache, extrapyramidal frustration (tremor of extremities and increase in a muscle tone, hypokinesia).
From the alimentary system: dryness in a mouth, pain in epigastric area, dyspepsia, cholestatic jaundice.
From integuments: perspiration, development of a volchanochnopodobny syndrome, red flat deprive (extremely seldom), skin rash.
Others: Allergic reactions, lowering of arterial pressure, increase in body weight.

Interaction with other medicines:

Strengthens effect of alcohol and sedatives. At simultaneous use with nootropic, anti-hypertensive and with sudorasshiryayushchy means strengthens their effect, and at simultaneous use with the drugs which are appointed at arterial hypotension - reduces their effect.

Contraindications:

Hypersensitivity, pregnancy, lactation period. With care at Parkinson's disease.

Overdose:

The maximum recommended dose should not exceed 225 mg (9 tablets) a day. In case of overdose there is no specific antidote, it is necessary to make a gastric lavage and to accept
absorbent carbon.

Treatment - symptomatic.

Storage conditions:

In the dry, protected from light place at a temperature not over 25 ºС. To store in the place, unavailable to children. Period of validity 2 years.

Issue conditions:

According to the recipe

Packaging:

Tablets on 0,025 g.
On 10, 50 tablets in a blister strip packaging from a film of the polyvinyl chloride and printing aluminum foil varnished. On 10, 20, 30, 40, 50 or 100 tablets in banks polymeric for medicines.
To one bank or 1, 2, 3, 4, 5 or 10 contour of ny strip packagings together with the application instruction place in cardboard packaging (pack).